The Supreme Court recently made a significant ruling regarding the regulation of the abortion pill mifepristone. The court rejected a lawsuit challenging the FDA's approach to regulating the pill, which will allow the pills to continue to be mailed to patients without requiring an in-person doctor's visit.
This ruling marks a setback for the anti-abortion movement and is the first major Supreme Court case on reproductive rights since the court's conservative majority overturned Roe v. Wade in 2022. The court determined that the doctors and anti-abortion groups lacked standing to sue over access to the drug.
